Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04625907
Title	FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma (FaR-RMS)
Acronym	FaR-RMS
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	University of Birmingham
Indications	rhabdomyosarcoma
Therapies	Irinotecan + Temozolomide + Vincristine Sulfate Dactinomycin + Ifosfamide + Vincristine Sulfate Irinotecan + Regorafenib + Vincristine Sulfate Dactinomycin + Ifosfamide + Irinotecan + Vincristine Sulfate Dactinomycin + Doxorubicin + Ifosfamide + Vincristine Sulfate Cyclophosphamide + Vinorelbine
Age Groups:	senior \| adult \| child
Covered Countries	SWE \| SVN \| SVK \| NZL \| NOR \| NLD \| ITA \| ISR \| IRL \| GRC \| GBR \| FRA \| ESP \| DNK \| CZE \| CHE \| BEL \| AUT \| AUS